| |
Klinik und Poliklinik für Urologie und Kinderurologie
| 2025 |
Einrichtungsstatistik
|
| Forschungsprojekte | 20 |
| Publikationen | 6 |
| Promotionen | 2 |
 |
|
|
Projektleiter: PD Dr. med. Maximilian Brandt, PD Dr. Rene Mager, Dr. Anita Thomas
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)Compare efficacy of durvalumab + tremelimumab + EV relative to cystectomy on pCR rate and EFS Compare the efficacy of durvalumab + EV relative to cystectomy on pCR rate, EFS, OS, EFS24, OS5, DFS, pDS rate, DSS, and metastasis-free survival (MFS) Compare the efficacy of durvalumab + tremelimumab + EV relative to cystectomy on OS, EFS24, OS5, DFS, pDS rate, DSS, and MFS |
Laufzeit: 2022-2026 |
|
Projektleiter: PD Dr. Maximilian Brandt, Dr. Anita Thomas
ARTEMIS STUDYProspective, Multi-country, Comparative Observational Study (non-interventional) of clinical outcomes that benefit mHSPC patients treated with Apalutamide + ADT and Enzalutamide+ADT under routine clinical practice (ARTEMISpro)Patients with metastatic hormone sensitive prostate cancer (mHSPC). |
Laufzeit: 2023-2025 |
|
Projektleiter: Dr. Maximilian Brandt, Dr. Anita Thomas
BAY 88-8223 / 20510 RADIANTA Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer progressing on/after one line of NAH |
Laufzeit: 2021-2025 |
|
Projektleiter: PD Dr. Maximilian Brandt, PD Dr. Rene Mager
BMS CA17-078: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle Invasive Bladder CancerTo compare the pCR rate of neoadjuvant nivolumab/BMS-986205 + GC to neoadjuvante alone in all randomize participants.
To compare EFS of neoadjuvant nivolumab/BMS-986205 +
GC followed by continued nivolumab/BMS-986205 after
RC versus SOC GC followed by RC in all randomized
participants.
Sekundäre Endpunkte/Zielsetzungen:
To compare overall survival (OS) of neoadjuvant nivolumab/BMS-986205 + GC or nivolumab + GC followed by continued IO therapy after RC versus neoadjuvant SOC GC followed by RC in all randomized participants (Arm C vs Arm A and Arm B vs Arm A).
To describe the safety and tolerability of nivolumab and
nivolumab/BMS-986205 in combination with GC
chemotherapy. |
Laufzeit: 2019-2025 |
|
Projektleiter: Dr. Dr. Gregor Duwe, PD Dr. Thomas Höfner, Univ.-Prof. Dr. Axel Haferkamp
KITTU - KI-unterstützte Therapiebegleitung am Beispiel der Urologie“/ AI-supported support in treatment recommendation for cancer patients in urologyIn Western countries approximately every fourths new cancer diagnosis belongs to the urinary and genital organs. Recommending the best therapy is complex and has to take into account the individuality of each patients medical history as well as an extensive knowledge that can hardly be surveyed by individual experts. KITTU („KI-unterstützte Therapiebegleitung am Beispiel der Urologie“/ AI-supported support in treatment recommendation for cancer patients in urology) aims to develop an AI- system that supports the treatment of tumor patients in urology by demonstrating physicians and patients each therapeutic option available in their individual situation and supporting them in their decision-making process. KITTU thus contributes to relieving the burden on those involved in the process and to optimizing therapy decisions. With the help of KITTU we aim to increase evidence-based treatment recommendation in oncology in order to improve the quality of treatment and long-term survival of patients. Additionally, preventable side effects should be reduced while and overall quality of life will be improved. Once established in urology, the goal is to extend KITTU to other oncological diseases, thus enabling a significant improvement cancer care. |
Laufzeit: 2022-2025 |
|
Projektleiter: Univ.-Prof. Dr. Axel Haferkamp, Elke Tafel-Stein
Prostate Cancer Outcome (PCO) StudieIn der PCO-Studie wird erstmalig die Lebensqualität von Patienten mit Prostatakarzinom mit einem weltweit einheitlichen Patientenfragebogen gemessen. |
Laufzeit: 2016-2030 |
|
Projektleiter: PD Dr. Dr. Eva Juengel, Dr. Sascha Markowitsch
Antitumoral effects of sanguinarine on the growth behavior of renal cell carcinoma in vitroInvestigations of the antitumoral efficacy of sanguinarine from Traditional Chinese Medicine (TCM) on the progressive growth of renal cell carcinoma cells. |
Laufzeit: 2023-2027 |
|
Projektleiter: PD Dr. Dr. Eva Juengel, Dr. Sascha Markowitsch
Integration of artesunate into a cabozantinib-based therapy concept of renal cell carcinoma in vitroIn the current study we investigate whether artesunate, from Traditional Chinese Medicine (TCM), simultaneously applied with the tyrosine kinase inhibitor (TKI) cabozantinib might induce additive or synergistic antitumor effects in renal cell carcinoma cells. |
Laufzeit: 2023-2026 |
|
Projektleiter: PD Dr. Dr. Eva Juengel, Prof. Dr. Roman Blaheta
The impact of mistletoe (Iscuin) preparation on cell death induction and associated metabolism in urologic tumor cellsMistletoe preparations are administered in alternative medicine for various tumor entities. However, the data situation is incomplete. Little is known about effects on urologic tumors. Initial studies showed an antitumor effect of mistletoe preparations on urologic tumor cells. More in-depth analyses should now further investigate the antitumor effects of mistletoe preparations from different host plants on various urologic tumor entities. In particular, the induction of different types of cell death, the formation of reative oxygene species and the influence on cell matabolism after treatment of prostate, bladder and renal cell carcinoma cell lines with different mistletoe extracts will be investigated. |
Laufzeit: 2023-2025 |
|
Projektleiter: PD Dr. Dr. Eva Jüngel, Dr. Sascha Markowitsch
Preclinical studies to integrate the natural compound sanguinarine into an established first-line treatment for renal cell carcinomaThe planned studies will investigate whether sanguinarine in combination with cabozantinib inhibits the progressive growth behavior of renal cell carcinoma (RCC) in a synergistic or additive manner. Alterations in cell cycle dysregulation and cell death induction as well as modulation of proteins involved will be evaluated. The objective is to determine if and to what extent sanguinarine supports guideline-directed therapy with cabozantinib in RCC cells and to identify the underlying mechanisms. The long-term goal is to provide a more effective treatment option for patients with advanced RCC. |
Laufzeit: 2024-2026 |
|
Projektleiter: PD Dr. Rene Mager, Dr. Maximilian Brandt, PD Dr. Anita Thomas
Exelixis CL184-313A Randomized, Double-Blind, Controlled Phase 3 Study of
Cabozantinib in Combination with Nivolumab and Ipilimumab
versus Nivolumab and Ipilimumab in Subjects with Previously
Untreated Advanced or Metastatic Renal Cell Carcinoma of
Intermediate or Poor Risk |
Laufzeit: 2020-2025 |
|
Projektleiter: PD Dr. Rene Mager, PD Dr. Maximilian Brandt, PD Dr. Anita Thomas
MK3475-564: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma PostDas Ziel dieser klinischen Prüfung ist:
• die Sicherheit und die Verträglichkeit der Prüfmedikation Pembrolizumab (andere Bezeichnung: MK-3475) zu überprüfen;
• die Wirksamkeit von Pembrolizumab im Vergleich mit Placebo (einem identisch aussehenden Präparat ohne Wirkstoff) zu überprüfen. |
Laufzeit: 2017-2025 |
|
Projektleiter: PD Dr. René Mager
: Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent therapy lines in the era of immunotherapy (ReSeq study)Beschreibung: The objective is to investigate, if primary resistance to 1st line TKI monotherapy predicts response to ICI in subsequent therapy lines and impacts overall survival (OS) in metastatic renal cell carcinoma. |
Laufzeit: 2022-2025 |
|
Projektleiter: Dr. Stephanie Neuberger
Prospektive Erhebung des Antikörperverlaufs (IgG Anti-Spike-Protein) vor und nach einer Booster-Impfung gegen SARS-Cov-2 an einem uroonkologischen Kollektiv unter TherapieEinleitung:
Ziel der klinischen Studie ist es an einem Kollektiv mit uroonkologischen Patienten einen Antikörperverlauf darzustellen vor und nach einer Booster-Impfung mit einem Impfstoff gegen SARS-Cov2.
Inhalt:
50 Patienten mit einer uroonkologischen Diagnose (Prostatakarzinom, Urothelkarzinom, Nierenzellkarzinom) und unter palliativer medikamentöser Tumortherapie (Antihormonelle Therapie, Chemotherapie, Immuntherapie, Target Therapy) wird vor der Boosterimpfung, 4-8 Wochen nach der Booster-Impfung und 6 Monate nach der Boosterimpfung 1 Serumröhrchen (7,5ml) im Rahmen der routinemäßigen Blutentnahme abgenommen für die Anitkörperbestimmung (IgG Anti-Spike-Protein). Auch werden folgende Daten erhoben: Persönliche Daten, Diagnose, Therapie, Datum der abgeschlossenen Erstimpfung, Datum der Boosterimpfung, Impfreaktionen, Nebenwirkungen der Tumortherapie.
Ziel:
Evaluation des Antikörperverlaufs und Darstellung möglicher Unterschiede auf das Impfansprechen zwischen den verschiedenen Therapieregimen |
Laufzeit: 2022-2025 |
|
Projektleiter: Prof. Dr. Annette Schröder
Untreated distal Hypospadias - Natural history of the foreskinMulticenter Studie |
Laufzeit: 2022-2025 |
|
Projektleiter: Dr. Peter Sparwasser
ReTraNUXretro- versus transperitoneale robotische NUX à klinische Studie aktuell 8 Patienten rekrutiert (Ziel: 42) |
Laufzeit: 2022-2026 |
|
Projektleiter: Dr. Anita Thomas, Dr. Robert Dotzauer
A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN)A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer |
Laufzeit: 2014-2025 |
|
Projektleiter: Dr. Anita Thomas
Biomarker PenisPrediktive und prognostische Bedeutung der Proteinbiomarker beim Peniskarzinom |
Laufzeit: 2020-2026 |
|
Projektleiter: Dr. Anita Thomas
Biomarker Prostata Evaluation neuer Biomarker beim ProstatakarzinomSuche nach neuen empfindlichen Biomarkern für die Optimierung der Diagnostik und Therapie des Prostatakarzinoms in Blut und Urinproben von Patienten mit diagnostiziertem PCA |
Laufzeit: 2020-2026 |
|
Projektleiter: Dr. Anita Thomas
ProblaneEinfluss vom anatomischen Blasenhalserhalt auf funktionelle und onkologische Ergebnisse nach der robotisch-assistierten laparoskopischen radikalen Prostatovesikulektomie (RALP) |
Laufzeit: 2020-2027 |
|
|
|
|
Blaheta Roman A., Han Jiaoyan, Oppermann Elsie, Bechstein Wolf Otto, Burkhard Katrin, Haferkamp Axel, Rieger Michael A., Malkomes Patrizia
Autoren der Einrichtung:
Blaheta Roman A., Haferkamp Axel
Transglutaminase 2 promotes epithelial-to-mesenchymal transition by regulating the expression of matrix metalloproteinase 7 in colorectal cancer cells via the MEK/ERK signaling pathway
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2025; 1871 (1): Article
Datensatz in Web of Science®
|
|
|
Del Giudice Francesco, Vestri Annarita, Fegatelli Danilo Alunni, Huesch Tanja, Belsey Jonathan, Nair Rajesh, Skinner Eila C., Chung Benjamin I., Pecoraro Martina, Sciarra Alessandro, Franco Giorgio, Pradere Benjamin, Gazzaniga Paola, Magloicca Fabio Massimo, Panebianco Valeria, De Berardinis Ettore
Autoren der Einrichtung:
Huesch Tanja
VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-<i>less</i>' Randomised Trial Protocol
BJU INTERNATIONAL. 2025; 135 (2): 346-354 Article
Datensatz in Web of Science®
|
|
|
Giannini Giulia, Kafka Mona, Neuwirt Hannes, Artamonova Nastasiia, di Santo Gianpaolo, Virgolini Irene, Dotzauer Robert, Deiss Emil, Paffenholz Pia, Heidenreich Axel, Rasul Sazan, Tsaur Igor, Rausch Steffen, Einspieler Holger, la Fougere Christian, Trautwein Nils F., Zattoni Fabio, Sepulcri Matteo, Heidegger Isabel
Autoren der Einrichtung:
Dotzauer Robert
Safety and Efficacy of 177 Lu-PSMA Therapy Following 223 Radium Treatment: A Retrospective Multinational Real-World Analysis
CLINICAL GENITOURINARY CANCER. 2025; 23 (1): Article
Datensatz in Web of Science®
|
|
|
Mager Rene, Tsaur Igor, Hoefner Thomas, Gheith Mohamed Kamal, Duwe Gregor, Haack Maximilian, Azar Jonathan, Aboulmaouahib Brahim, Ziewers Stefanie, Sparwasser Peter, Frey Lisa, Thomas Anita, Haferkamp Axel
Autoren der Einrichtung:
Mager Rene, Tsaur Igor, Hoefner Thomas, Gheith Mohamed Kamal, Duwe Gregor, Haack Maximilian, Azar Jonathan, Ziewers Stefanie, Sparwasser Peter, Frey Lisa, Thomas Anita, Haferkamp Axel
Weitere Autoren des Fachbereichs:
Aboulmaouahib Brahim
Retroperitoneal Versus Transperitoneal Robot Assisted Partial Nephrectomy: A Prospective Controlled Non-Randomized Single Centre Study Non-Inferiority Design
INTERNATIONAL JOURNAL OF MEDICAL ROBOTICS AND COMPUTER ASSISTED SURGERY. 2025; 21 (3): 7 Article
Datensatz in Web of Science®
|
|
|
Stenzel P. J., Tagscherer K. E., Justenhoven C., Wild P. J., Haferkamp A., Macher-Goeppinger S., Roth W., Frees S., Porubsky S.
Autoren der Einrichtung:
Haferkamp A., Frees S.
Weitere Autoren des Fachbereichs:
Stenzel P. J., Tagscherer K. E., Macher-Goeppinger S., Roth W., Porubsky S.
RCC-Ma loss predicts poor survival and metastatic risk in clear cell renal cell carcinoma
PATHOLOGY RESEARCH AND PRACTICE. 2025; 269: Article
Datensatz in Web of Science®
|
|
|
Stenzel P. J., Thomas A., Schindeldecker M., Macher-Goeppinger S., Porubsky S., Haferkamp A., Tsaur I., Roth W., Tagscherer K. E.
Autoren der Einrichtung:
Thomas A., Haferkamp A.
Weitere Autoren des Fachbereichs:
Stenzel P. J., Schindeldecker M., Macher-Goeppinger S., Porubsky S., Roth W., Tagscherer K. E.
Tumor-infiltrating plasma cells are a prognostic factor in penile squamous cell carcinoma
VIRCHOWS ARCHIV. 2025: Article
Datensatz in Web of Science®
|
|
|
|
|
Alexandra Sita Ober
Beckenbodeninsuffizienz im Zeitalter der Digitalisierung: Evaluierung von Kontext und Informationsgehalt in digitalen Medien
|
|
|
Tim Schykowski
Evaluation von Komplikationen der transperinealen Prostatabiopsie ohne periinterventionelle Antibiotika-Prophylaxe und ohne präinterventionelles Screening für Bakteriurie - eine monozentrische retrospektive klinische Studie
|
|
|
|
|
|
|
